Ryan J. Watts, Kathryn M. Monroe, Junhua Wang, Melina Lenser, Jennifer Hsiao-Nakamoto, Hoang Nguyen, Todd P. Logan, Do Jin Kim, Fen Huang, Ritesh Ravi, Gilbert Di Paolo, Anil Rana, Kannan Gunasekaran, Yaneth Robles-Colmenares, Gerald M. Cherf, Buyankhishig Tsogtbaatar, Ceyda Llapashtica, Kirk R. Henne, Hilda Solanoy, Pascal E. Sanchez, Yashas Rajendra, Mihalis Kariolis, Ray Lieh Yoon Low, Roni Chau, Laralynne Przybyla, Michelle E. Pizzo, Chi-Lu Chiu, Meng Fang, Anastasia G. Henry, Giuseppe Astarita, Mark S. Dennis, Adam L. Boxer, Sarah L. DeVos, Sonnet S. Davis, Hilary W. Heuer, René Meisner, Joseph W. Lewcock, Devendra B. Srivastava, Bradley F. Boeve, Meredith E. K. Calvert, Katrina W. Lexa, Rachel Prorok, Lukas L. Skuja, Dolores Diaz, Akhil Bhalla, Matthew Simon, Jung H. Suh, Ankita Srivastava, Timothy K. Earr, Howard J. Rosen, Joseph Duque, Bettina Van Lengerich, and Elizabeth W. Sun
GRN mutations cause frontotemporal dementia (GRN-FTD) due to deficiency in progranulin (PGRN), a lysosomal and secreted protein with unclear function. Here, we found that Grn(−/−) mice exhibit a global deficiency in bis(monoacylglycero)phosphate (BMP), an endolysosomal phospholipid we identified as a pH-dependent PGRN interactor as well as a redox-sensitive enhancer of lysosomal proteolysis and lipolysis. Grn(−/−) brains also showed an age-dependent, secondary storage of glucocerebrosidase substrate glucosylsphingosine. We investigated a protein replacement strategy by engineering protein transport vehicle (PTV):PGRN – a recombinant protein linking PGRN to a modified Fc domain that binds human transferrin receptor for enhanced CNS biodistribution. PTV:PGRN rescued various Grn(−/−) phenotypes in primary murine macrophages and human iPSC-derived microglia, including oxidative stress, lysosomal dysfunction and endomembrane damage. Peripherally delivered PTV:PGRN corrected levels of BMP, glucosylsphingosine and disease pathology in Grn(−/−) CNS, including microgliosis, lipofuscinosis and neuronal damage. PTV:PGRN thus represents a potential biotherapeutic for GRN-FTD.